DS
Therapeutic Areas
Biocon Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Bmab 1200 (Bevacizumab biosimilar) | NSCLC, Colorectal Cancer, Others | Approved |
| Bmab 1000 (Trastuzumab biosimilar) | HER2+ Breast & Gastric Cancer | Approved |
| Bmab 1100 (Pegfilgrastim biosimilar) | Chemotherapy-induced Neutropenia | Approved |
| Bmab 1300 (Adalimumab biosimilar) | Rheumatoid Arthritis, Psoriasis, Others | Approved |
| Insulin Aspart biosimilar | Diabetes | Approved |
| Bmab 1400 (Denosumab biosimilar) | Osteoporosis, Bone Metastasis | Phase III |
| Bmab 1500 (Ustekinumab biosimilar) | Psoriasis, Crohn's Disease | Phase III |
| Bmab 1600 (Aflibercept biosimilar) | Wet AMD, Diabetic Macular Edema | Phase III |